Posters

Visual performance, patient satisfaction, and stability of new RayOne trifocal IOL: our results

Poster Details

First Author: A.Mularoni SAN MARINO

Co Author(s):    A. Imburgia   L. Rania   G. Mussoni              

Abstract Details

Purpose:

To report visual performance, patient satisfaction, stability and posterior capsular opacification (PCO) incidence in 6 patients who underwent bilateral cataract surgery with implantation of new RayOne (Rayner) trifocal intraocular lens.

Setting:

Department of Ophthalmology - San Marino Hospital - Chief: Dr A. Mularoni

Methods:

A total of 12 eyes (6 patients) were evaluated after implantation of trifocal IOL RayOne. Uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), contrast sensitivity and reading performance with MNread charts were assessed at 1, 3 and 6 months postoperatively. To evaluate patient satisfaction, a questionnaire was administered and compiled by the patients 1 and 3 months after surgery. PCO incidence and IOL stability were assessed by digital photos of anterior segment during the follow up.

Results:

All eyes achieved UCVA distance of 0.10 logMAR or better (Snellen 20/25) at 6 months postoperatively. 100% (12 eyes) of eyes achieved a postoperative uncorrected intermediate and near visual acuity of 20/25 or more (LogMAR 0,1). Postoperative contrast sensitivity values were within the ranges of normality for all spatial frequencies evaluated. Postoperative spectacle independence and patient satisfaction was very high, with most of the patients reporting a good or very good visual quality at far, intermediate and near distances. No PCO was reported during the first 6 months follow up; IOL centration was stable at 6 months after surgery.

Conclusions:

The evaluated RayOne trifocal IOL provides a very good performance of the visual function after cataract surgery, with high levels of distance, intermediate and near visual acuity, strong reading performance, patient satisfaction, no PCO incidence and high stability of IOL centration.

Financial Disclosure:

None